A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma

Chawla Sant P.; Chua Victoria S.; Hendifar Andrew F.; Quon Doris V.; Soman Neelesh; Sankhala Kamalesh K.; Wieland D. Scott; Levitt Daniel J.

首页> 外文期刊>Cancer: A Journal of the American Cancer Society >A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma

【24h】

A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma

机译：阿德柔比星在软组织肉瘤患者中的1B / 2期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BACKGROUNDAldoxorubicin, a prodrug of doxorubicin, covalently binds to serum albumin, allowing for the administration of much higher doses of doxorubicin in a previous clinical study. The current phase 1B/2 study evaluated the safety of aldoxorubicin, including preliminary efficacy and safety of its maximum tolerated dose (MTD).

机译：背景技术阿霉素（阿霉素的前药）与血清白蛋白共价结合，从而在先前的临床研究中允许施用更高剂量的阿霉素。当前的1B / 2期研究评估了阿霉素的安全性，包括初步疗效和最大耐受剂量（MTD）的安全性。

著录项

来源
《Cancer: A Journal of the American Cancer Society》 |2015年第4期|共10页
作者
Chawla Sant P.; Chua Victoria S.; Hendifar Andrew F.; Quon Doris V.; Soman Neelesh; Sankhala Kamalesh K.; Wieland D. Scott; Levitt Daniel J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
doxorubicin; maximum tolerated dose; prodrugs; serum albumin; soft tissue sarcoma;

机译：阿霉素;最大耐受剂量;前药;血清白蛋白;软组织肉瘤;

相似文献

外文文献
中文文献
专利

1. A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma [J] . Chawla Sant P., Chua Victoria S., Hendifar Andrew F., Cancer: A Journal of the American Cancer Society . 2015,第4期

机译：阿德柔比星在软组织肉瘤患者中的1B / 2期研究
2. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). [J] . Sleijfer S, Ray Coquard I, Papai Z Journal of Clinical Oncology . 2009,第19期

机译：Pazopanib是一种多激酶血管生成抑制剂，用于患有复发性或难治性晚期软组织肉瘤的患者：来自欧洲组织的研究和治疗癌症软组织和骨肉瘤组的II期研究（EORTC研究62043）。
3. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapya European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072) [J] . Coens Corneel, van der Graaf Winette T. A., Blay Jean-Yves, Cancer: A Journal of the American Cancer Society . 2015,第17期

机译：PALETTE得出的与健康有关的生活质量结果：帕唑帕尼与安慰剂治疗在先前化疗期间或之后疾病已进展的软组织肉瘤患者的一项随机，双盲，3期临床试验a欧洲研究和治疗软组织癌的组织组织和骨肉瘤组全球网络研究（EORTC 62072）
4. Deep multi-modality collaborative learning for distant metastases predication in PET-CT soft-tissue sarcoma studies [C] . Yige Peng, Lei Bi, Yuyu Guo, . 2019

机译：PET-CT软组织肉瘤研究中针对远处转移预测的深度多模式协作学习
5. Near-Infrared Spectroscopy to Assess Exercise-Induced Changes in Skeletal Muscle Oxygenation in Patients with Soft Tissue Sarcoma: A Preliminary Investigation [D] . Hoselton, Andrew Lewis. 2021

机译：近红外光谱，评估软组织肉瘤患者骨骼肌氧合的运动诱导的变化：初步调查
6. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group [O] . P A Cassier, A Lefranc, E Y Amela, 2013

机译：Panobinostat治疗晚期软组织肉瘤的II期临床试验。法国肉瘤组织的一项研究
7. A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study [O] . Pappo Alberto S., Vassal Gilles, Crowley John J., 2014

机译：R1507的第2阶段试验，一种针对胰岛素样生长因子-1受体（IGF-1R）的单克隆抗体，用于复发性或难治性横纹肌肉瘤，骨肉瘤，滑膜肉瘤和其他软组织肉瘤患者：肉瘤联盟的结果通过协作研究进行研究

A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅